Magellan Diagnostics

Magellan Biosciences is provider of point-of-care analyzers and automated systems for hospital-based labs and near-patient testing.

Launch date

1960

Employees

Market cap

Enterprise valuation

CAD90m (Public information from Mar 2016)

Billerica Massachusetts (HQ)

Date	Investors	Amount	Round
Nov 2006	Abingworth Nexus Medical Partners Tekla Capital Management KBL Healthcare Ventures Ampersand Capital Partners Boston Community Venture Fund New England Partners	$50.0m	Growth Equity VC
Mar 2016	Meridian Bioscience	$66.0m Valuation: $66.0m	Acquisition
Total Funding		CAD68.2m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Magellan Diagnostics